| Literature DB >> 34422525 |
Sarah J Plachinski1, Lucas M Boehm1, Karri A Adamson1, John A LoGiudice1, Erin L Doren1.
Abstract
Recent advances in mastectomy and reconstruction have allowed for an evolution in implant-based breast reconstruction to a muscle-sparing, prepectoral approach. Advantages of this technique may include reductions in postoperative pain, shorter hospitalization, less narcotic usage, and improved aesthetic outcomes. Postoperative complication rates are described as comparable to subpectoral techniques; however, little comparative data exist to adequately assess prepectoral versus subpectoral implant placement.Entities:
Year: 2021 PMID: 34422525 PMCID: PMC8376352 DOI: 10.1097/GOX.0000000000003709
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Patient Characteristics
| Characteristic | Prepectoral (%) N = 83 | Subpectoral (%) N = 103 |
| Total (%) |
|---|---|---|---|---|
| No. reconstructions | 83 | 103 | 186 | |
| Mean age ± SD, y | 47.88 ± 11.90 | 49.90 ± 12.46 | 0.263 | 49.00 ± 12.22 |
| Mean length of follow-up, mo | 15.59 ± 8.98 | 21.39 ± 12.00 | <0.001 | 18.80 ± 11.11 |
| Mean BMI | 28.12 ± 6.41 | 26.14 ± 5.40 | 0.023 | 27.03 ± 5.94 |
| Race | ||||
| White | 67 (80.7%) | 92 (89.3%) | 0.098 | 159 (85.5%) |
| Non-White | 16 (19.3%) | 11 (10.7%) | 27 (14.5%) | |
| Cancer stage | ||||
| 0 | 15 (18.1%) | 17 (16.5%) | 0.206 | 32 (17.2%) |
| 1 | 35 (42.2%) | 30 (29.1%) | 65 (34.9%) | |
| 2 | 20 (24.1%) | 40 (38.8%) | 60 (32.3%) | |
| 3 | 6 (7.2%) | 5 (4.9%) | 11 (5.9%) | |
| 4 | 2 (2.4%) | 1 (1.0%) | 3 (1.6%) | |
| Prophylactic | 5 (6.0%) | 10 (9.7%) | 15 (8.1%) | |
| Chemotherapy | ||||
| Neoadjuvant (± adjuvant) | 24 (28.9%) | 28 (27.2%) | 0.927 | 52 (28.0%) |
| Adjuvant | 13 (15.7%) | 15 (14.6%) | 28 (15.1%) | |
| Radiation | 17 (20.5%) | 31 (30.1%) | 0.136 | 48 (25.8%) |
| Diabetes | 2 (2.4%) | 4 (3.9%) | 0.693 | 6 (3.2%) |
| Smoking | ||||
| Never | 63 (75.9%) | 72 (69.9%) | 0.362 | 135 (72.6%) |
| Past or present | 20 (24.1%) | 31 (30.1%) | 51 (27.4%) |
*Statistically significant.
Procedure Characteristics
| Characteristic | Prepectoral (%) N = 83 | Subpectoral (%)N = 103 |
| Total (%) |
|---|---|---|---|---|
| Laterality | ||||
| Unilateral | 37 (44.6%) | 52 (50.5%) | 0.423 | 89 (47.8%) |
| Bilateral | 46 (55.4%) | 51 (49.5%) | 97 (52.2%) | |
| Surgery type | ||||
| Immediate TE | 57 (68.7%) | 81 (78.6%) | 0.123 | 138 (74.2%) |
| Immediate implant | 26 (31.3%) | 22 (21.4%) | 48 (25.8%) | |
| Total surgery time (min) | 335.10 ± 72.54 | 331.37 ± 75.42 | 0.743 | 333.16 ± 73.86 |
| ADM usage | ||||
| Yes | 58 (69.9%) | 93 (90.3%) | <0.001 | 151 (81.2%) |
| No | 25 (30.1%) | 10 (9.7%) | 35 (18.8%) | |
| Mean mastectomy weight (g) | 559.61 ± 346.75 | 428.49 ± 237.31 | 0.003 | 487.00 ± 297.68 |
| Missing** | 26 | 22 | 48 | |
| Intraoperative TE fill (ml) | 348.68 ± 200.19 | 234.81 ± 127.00 | <0.001 | 281.85 ± 170.19 |
| as % of final fill volume | 67.26 ± 23.76 | 53.33 ± 22.32 | <0.001 | 58.59 ± 24.01 |
| Missing** | 31 | 31 | 62 |
*Statistically significant. **Indicates the number missing from sample size indicated in the table header.
Postoperative Complications
| Characteristic | Prepectoral (%) | Subpectoral (%) |
| Total (%) |
|---|---|---|---|---|
| Any complication | ||||
| Yes | 38 (45.8%) | 36 (35.0%) | 0.134 | 74 (39.8%) |
| No | 45 (54.2%) | 67 (65.0%) | 112 (60.2%) | |
| Major complication | ||||
| Yes | 25 (30.1%) | 31 (30.1%) | 0.997 | 56 (30.1%) |
| No | 58 (69.9%) | 72 (69.9%) | 130 (69.9%) | |
| Minor complication | ||||
| Yes | 18 (21.7%) | 8 (7.8%) | 0.006 | 26 (14.0%) |
| No | 65 (78.3%) | 95 (92.2%) | 160 (86.0%) | |
| Infection | ||||
| Yes | 19 (22.9%) | 25 (24.3%) | 0.826 | 44 (23.7%) |
| No | 64 (77.1%) | 78 (75.7%) | 141 (76.3%) | |
| Infection treatment | ||||
| Surgery | 14 (73.7%) | 19 (76.0%) | 1.000 | 33 (75.0%) |
| Oral antibiotics | 1 (5.3%) | 2 (8.0%) | 3 (6.8%) | |
| IV antibiotics | 4 (21.1%) | 4 (16.0%) | 8 (18.2%) | |
| Mastectomy skin necrosis | ||||
| Inpatient | 5 (6.0%) | 2 (1.9%) | 0.245 | 7 (3.8%) |
| Outpatient | 0 (0.0%) | 1 (1.0%) | 1 (0.5%) | |
| None | 78 (94.0%) | 100 (97.1%) | 178 (95.7%) | |
| Seroma | ||||
| Yes | 17 (20.5%) | 5 (4.9%) | 0.001 | 22 (11.8%) |
| No | 66 (79.5%) | 98 (95.1%) | 164 (88.2%) | |
| Loss of TE/implant | ||||
| Yes | 11 (13.3%) | 22 (21.4%) | 0.150 | 33 (17.7%) |
| No | 72 (86.7%) | 81 (78.6%) | 153 (82.3%) | |
| Hematoma | ||||
| Yes | 4 (4.8%) | 5 (4.9%) | 1.000 | 9 (4.8%) |
| No | 79 (95.2%) | 98 (95.1%) | 177 (95.2%) | |
| Implant exposure | ||||
| Yes | 1 (1.2%) | 2 (1.9%) | 1.000 | 3 (1.6%) |
| No | 82 (98.8%) | 101 (98.1%) | 183 (98.4%) | |
| Wound dehiscence | ||||
| Yes | 3 (3.6%) | 0 (0.0%) | 0.087 | 3 (1.6%) |
| No | 80 (96.4%) | 103 (100.0%) | 183 (98.4%) | |
| Animation deformity | ||||
| Yes | 1 (1.2%) | 12 (11.7%) | 0.005 | 13 (7.0%) |
| No | 82 (98.8%) | 91 (88.3%) | 173 (93.0%) | |
| Capsular contracture | ||||
| Baker grade 2 | 16 (19.3%) | 20 (19.4%) | 0.791 | 36 (19.4%) |
| Baker grade 3 | 5 (6.0%) | 7 (6.8%) | 12 (6.5%) | |
| Baker grade 4 | 4 (4.8%) | 3 (2.9%) | 7 (3.8%) |
*Statistically significant.
†Loss of TE/implant means the device was removed and not replaced or removed and replaced due to a complication.
Operative Outcomes
| Characteristic | Prepectoral (%) | Subpectoral (%) |
| Total (%) |
|---|---|---|---|---|
| Mean no. clinic visits for TE expansion ± SD | 2.04 ± 1.49 | 3.34 ± 1.40 | <0.001 | 2.78 ± 1.57 |
| Missing | 27 | 29 | 56 | |
| Mean time to drain removal (d) ± SD | 26.90 ± 11.66 | 26.24 ± 10.84 | 0.702 | 26.54 ± 11.19 |
| Missing** | 5 | 10 | 15 | |
| Mean no. hospital readmissions ± SD | 0.51 ± 1.03 | 0.46 ± 0.80 | 0.583 | 0.49 ± 0.91 |
| Type of hospitalization | 42 (50.6%) | 72 (69.9%) | 0.007 | 114 (61.3%) |
| Outpatient | 41 (49.4%) | 31 (30.1%) | 0.007 | 72 (38.7%) |
| No. surgical revisions | ||||
| 0 | 18 (21.7%) | 30 (29.1%) | 0.017 | 48 (25.8%) |
| 1 | 56 (67.5%) | 49 (47.6%) | 105 (56.5%) | |
| 2 | 9 (10.8%) | 20 (19.4%) | 29 (15.6%) | |
| >2 | 0 (0.0%) | 4 (3.9%) | 4 (2.2%) | |
| No. fat grafting procedures | ||||
| 0 | 44 (53.0%) | 60 (58.3%) | 0.163 | 104 (55.9%) |
| 1 | 33 (39.8%) | 29 (28.2%) | 62 (33.3%) | |
| 2 | 6 (7.2%) | 11 (10.7%) | 17 (9.1%) | |
| >2 | 0 (0.0%) | 3 (2.9%) | 3 (1.6%) | |
| Mean (ml) fat grafted ± SD | 103.37 ± 61.25 | 113.93 ± 71.15 | 0.476 | 108.91 ± 66.43 |
| Missing** | 44 | 60 | 104 |
*Statistically significant. **Indicates the number missing from sample size indicated in the table header.
Pain Scores
| Characteristic | Prepectoral (%)N = 83 | Subpectoral (%) |
| Total (%) |
|---|---|---|---|---|
| Mean baseline pain score ± SD | 0.43 ± 1.34 | 0.40 ± 1.30 | 0.870 | 0.42 ± 1.31 |
| Missing** | 0 | 1 | 1 | |
| Mean POD1 pain score ± SD | 4.65 ± 1.68 | 4.44 ± 2.19 | 0.649 | 4.60 ± 1.81 |
| Missing** | 20 | 83 | 103 | |
| Mean clinic visit #1 pain score ± SD | 3.32 ± 3.07 | 2.80 ± 2.63 | 0.220 | 3.03 ± 2.84 |
| Missing** | 2 | 4 | 6 | |
| Mean clinic visit #2 pain score ± SD | 2.19 ± 2.45 | 2.36 ± 2.63 | 0.685 | 2.28 ± 2.54 |
| Missing** | 6 | 13 | 19 | |
| Prescriptions for muscle relaxants | ||||
| 0 | 71 (86.6%) | 14 (13.7%) | <0.001 | 85 (46.2%) |
| 1 | 9 (11.0%) | 69 (67.6%) | 78 (42.4%) | |
| >1 | 2 (2.4%) | 19 (18.6%) | 21 (11.4%) | |
| Prescriptions for narcotics | ||||
| 1 | 67 (81.7%) | 84 (83.2%) | 0.796 | 151 (82.5%) |
| >1 | 15 (18.3%) | 17 (16.8%) | 32 (17.5%) |
*Statistically significant. **Indicates the number missing from sample size indicated in the table header.
POD1, postoperative day 1.